|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Vanderbilt University |
|---|---|
| Information provided by: | Vanderbilt University |
| ClinicalTrials.gov Identifier: | NCT00592709 |
Purpose
We are collecting brain tissue specimens and blood samples from patients at Vanderbilt University Medical Center who are undergoing intracranial surgery to remove brain tissue, including brain tumors, tissue from epilepsy surgery and brain tissue removed during surgery for other non-cancerous types of brain tissus. These specimens will then be studied using a novel microscopic laser-directed protein mass spectrometric analysis, looking for unique protein signatures.
| Condition |
|---|
|
Brain Diseases |
| Study Type: | Observational |
| Official Title: | Analysis of Brain Tumors Using Matrix Assisted Laser Desorption/Ionization Mass Spectrometry |
Brain Tissue
| Estimated Enrollment: | 150 |
| Study Start Date: | May 2003 |
| Estimated Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
We are collecting brain tissue specimens and blood samples from patients at Vanderbilt University Medical Center who are undergoing intracranial surgery to remove brain tissue, including brain tumors, tissue from epilepsy surgery and brain tissue removed during surgery for other non-cancerous types of brain tissus. These specimens will then be studied using a novel microscopic laser-directed protein mass spectrometric analysis. Data from different brain tissues including tumors of different histological sub-types will be analyzed for unique protein signatures. These protein signatures will then be statistically correlated with clinical data including time to tumor progression and response to therapy.
The goal of this study is to determine molecular patterns that will be more predictive of tumor behavior, thus leading to an improved understanding of the basic biology of these poorly understood cancers. This in turn, may lead to more refined therapies and improved outcomes.
Eligibility| Ages Eligible for Study: | 2 Years to 85 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Age 2 years through Age 85 years old
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, Tennessee | |
| Vanderbilt University Medical Center, Department of Neurological Surgery | |
| Nashville, Tennessee, United States, 37232 | |
| Principal Investigator: | Reid C. Thompson, MD | Vanderbilt University Medical Center, Department of Neurological Surgery |
More Information
| Responsible Party: | Vanderbilt University Medical Center, Department of Neurological Surgery ( Reid C. Thompson, MD ) |
| Study ID Numbers: | 030258 |
| Study First Received: | January 2, 2008 |
| Last Updated: | January 11, 2008 |
| ClinicalTrials.gov Identifier: | NCT00592709 History of Changes |
| Health Authority: | United States: Institutional Review Board |
|
Brain Neoplasms Central Nervous System Diseases Central Nervous System Neoplasms Brain Diseases Nervous System Neoplasms |
|
Brain Neoplasms Neoplasms Neoplasms by Site Nervous System Diseases |
Central Nervous System Diseases Central Nervous System Neoplasms Brain Diseases Nervous System Neoplasms |
